$AGIO
AGIOS PHARMACEUTICALS, INC.

2023 Q4 Form 10-Q Financial Statement

#000143922223000140 Filed on November 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $7.103M $7.399M
YoY Change 64.8% 110.44%
Cost Of Revenue $586.0K $633.0K
YoY Change 41.89% 22.44%
Gross Profit $6.517M $6.766M
YoY Change 67.23% 125.61%
Gross Profit Margin 91.75% 91.44%
Selling, General & Admin $35.31M $25.82M
YoY Change 7.73% -11.33%
% of Gross Profit 541.74% 381.64%
Research & Development $77.49M $81.84M
YoY Change 10.23% 25.98%
% of Gross Profit 1189.03% 1209.59%
Depreciation & Amortization $1.423M $1.600M
YoY Change -21.55% -19.23%
% of Gross Profit 21.84% 23.65%
Operating Expenses $112.8M $107.7M
YoY Change 9.44% 65.72%
Operating Profit -$106.3M -$100.9M
YoY Change 7.16% 10.77%
Interest Expense $8.624M $8.375M
YoY Change 32.92% 119.36%
% of Operating Profit
Other Income/Expense, Net $1.713M $1.198M
YoY Change 26.23% 10.72%
Pretax Income -$95.94M -$91.32M
YoY Change -362.66% 11.71%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$95.94M -$91.32M
YoY Change -362.66% 11.72%
Net Earnings / Revenue -1350.7% -1234.27%
Basic Earnings Per Share -$1.64
Diluted Earnings Per Share -$1.72 -$1.64
COMMON SHARES
Basic Shares Outstanding 55.89M shares 55.74M shares
Diluted Shares Outstanding 55.80M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $776.9M $647.5M
YoY Change -0.79% -11.02%
Cash & Equivalents $88.21M $64.33M
Short-Term Investments $688.7M $583.2M
Other Short-Term Assets $35.02M $38.40M
YoY Change -10.1% -17.4%
Inventory $19.08M $17.27M
Prepaid Expenses
Receivables $2.810M $1.200M
Other Receivables $0.00 $0.00
Total Short-Term Assets $833.8M $704.4M
YoY Change 0.13% -10.27%
LONG-TERM ASSETS
Property, Plant & Equipment $15.38M $16.79M
YoY Change -33.08% -34.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $29.44M $224.9M
YoY Change -90.62% -24.62%
Other Assets $4.057M $4.057M
YoY Change 2.55% 3.95%
Total Long-Term Assets $103.3M $302.9M
YoY Change -74.56% -23.39%
TOTAL ASSETS
Total Short-Term Assets $833.8M $704.4M
Total Long-Term Assets $103.3M $302.9M
Total Assets $937.1M $1.007B
YoY Change -24.35% -14.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.780M $13.27M
YoY Change -47.46% 27.42%
Accrued Expenses $43.17M $30.49M
YoY Change 42.23% 2.47%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $67.96M $58.43M
YoY Change 8.5% 9.01%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $1.156M $1.156M
YoY Change -64.75% 9.57%
Total Long-Term Liabilities $1.156M $1.156M
YoY Change -64.75% 9.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $67.96M $58.43M
Total Long-Term Liabilities $1.156M $1.156M
Total Liabilities $126.1M $120.4M
YoY Change -8.56% -7.48%
SHAREHOLDERS EQUITY
Retained Earnings -$822.6M -$726.7M
YoY Change 74.82% 43.31%
Common Stock $2.437B $2.422B
YoY Change 2.1% 1.98%
Preferred Stock
YoY Change
Treasury Stock (at cost) $802.5M $802.5M
YoY Change 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity $811.0M $886.8M
YoY Change
Total Liabilities & Shareholders Equity $937.1M $1.007B
YoY Change -24.35% -14.66%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$95.94M -$91.32M
YoY Change -362.66% 11.72%
Depreciation, Depletion And Amortization $1.423M $1.600M
YoY Change -21.55% -19.23%
Cash From Operating Activities -$72.46M -$61.70M
YoY Change 9.52% -13.53%
INVESTING ACTIVITIES
Capital Expenditures $199.0K $400.0K
YoY Change 76.11% -1152.63%
Acquisitions
YoY Change
Other Investing Activities $95.77M $39.70M
YoY Change 15.3% -61.87%
Cash From Investing Activities $95.48M $39.40M
YoY Change 15.1% -62.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 833.0K 1.900M
YoY Change 3686.36% 60.07%
NET CHANGE
Cash From Operating Activities -72.46M -61.70M
Cash From Investing Activities 95.48M 39.40M
Cash From Financing Activities 833.0K 1.900M
Net Change In Cash 23.85M -20.40M
YoY Change 41.86% -160.17%
FREE CASH FLOW
Cash From Operating Activities -$72.46M -$61.70M
Capital Expenditures $199.0K $400.0K
Free Cash Flow -$72.66M -$62.10M
YoY Change 9.63% -12.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
209612000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
84598000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
88902000 usd
us-gaap Costs And Expenses
CostsAndExpenses
304930000 usd
us-gaap Costs And Expenses
CostsAndExpenses
299805000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-285210000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-289875000 usd
CY2023Q3 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
0 usd
CY2022Q3 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
4443000 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
0 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
9851000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1198000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1082000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-91324000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-81747000 usd
us-gaap Net Income Loss
NetIncomeLoss
-256148000 usd
us-gaap Net Income Loss
NetIncomeLoss
-268327000 usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.64
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.64
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.49
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.49
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54734301 shares
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-91324000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-81747000 usd
us-gaap Net Income Loss
NetIncomeLoss
-256148000 usd
us-gaap Net Income Loss
NetIncomeLoss
-268327000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2974000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4581000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-13885000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-88350000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-86328000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-249509000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-282212000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1100814000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
-4124000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2467000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10139000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-81018000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1036526000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
459000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
238000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11737000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1291975000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
6547000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1289000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15510000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-94774000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1207453000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19720000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9930000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2295000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1291000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
218037000 usd
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8375000 usd
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3818000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.90
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.90
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55803663 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55803663 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54844579 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54844579 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55559766 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55559766 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54734301 shares
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6639000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-83806000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1881000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9076000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
886843000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
2757000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11165000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-91806000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1124070000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
4581000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1272000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11156000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-81747000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
1050170000 usd
us-gaap Net Income Loss
NetIncomeLoss
-256148000 usd
us-gaap Net Income Loss
NetIncomeLoss
-268327000 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
5220000 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
6750000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
30952000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
37831000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4658000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-721000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-278000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-29000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
7967000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
7432000 usd
agio Asset Acquisition Expense
AssetAcquisitionExpense
17500000 usd
agio Asset Acquisition Expense
AssetAcquisitionExpense
0 usd
us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
28000 usd
us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1030000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1818000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
8782000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5176000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-604000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-440000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7655000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5201000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4628000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
140000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2211000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-10161000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-7646000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2123000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
779000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-223574000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-243315000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
327490000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
782218000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
488492000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
947296000 usd
agio Payments For Asset Acquisition
PaymentsForAssetAcquisition
17500000 usd
agio Payments For Asset Acquisition
PaymentsForAssetAcquisition
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
765000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4768000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1325000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
144062000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
160310000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
248000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4586000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2576000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4586000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2328000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-74926000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-80677000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
139259000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
203126000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64333000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122449000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
14000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
21000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
1586000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
1940000 usd
CY2022 agio Gain Loss On Sale Of Contingent Payments
GainLossOnSaleOfContingentPayments
127900000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the recent COVID-19 pandemic, or other pandemics or public health emergencies, may in the future directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are </span></div>highly uncertain. We have made estimates of the impact of the recent COVID-19 pandemic within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
872400000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
99000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
12634000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
957734000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
233 security
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
259 security
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
813953000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5896000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
808057000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
970269000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
808100000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
868200000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0 security
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0 security
CY2023Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
470000 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
0 usd
CY2023Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
15743000 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
7550000 usd
CY2023Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1061000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
942000 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
17274000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
8492000 usd
CY2023Q3 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P4Y
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
3807000 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
3807000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
11420000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
11420000 usd
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
4550000 usd
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
4420000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
13614000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
12610000 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.057
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.057
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y4M24D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y2M12D
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30490000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30350000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3037000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
18660000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
19507000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
20151000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
20755000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
3479000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
85589000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10091000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
75498000 usd
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
1700000 usd
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
1000000 usd
us-gaap Sublease Income
SubleaseIncome
4500000 usd
us-gaap Sublease Income
SubleaseIncome
2700000 usd
CY2023Q3 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
1247000 usd
CY2023Q3 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
5078000 usd
CY2023Q3 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
1310000 usd
CY2023Q3 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
7635000 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14022000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
18105000 usd
CY2023Q3 agio Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
12528000 usd
CY2022Q4 agio Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
8425000 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1369000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2435000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2571000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1385000 usd
CY2022Q4 agio Contract With Customer Contractual Adjustment Reserve
ContractWithCustomerContractualAdjustmentReserve
65000 usd
CY2022Q4 agio Contract With Customer Rebate Reserve
ContractWithCustomerRebateReserve
573000 usd
CY2022Q4 agio Contract With Customer Right To Recover Product Reserve
ContractWithCustomerRightToRecoverProductReserve
133000 usd
CY2022Q4 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
771000 usd
agio Current Year Provision For Contractual Adjustments
CurrentYearProvisionForContractualAdjustments
919000 usd
agio Current Year Provisions For Rebate Reserve
CurrentYearProvisionsForRebateReserve
1631000 usd
agio Provision For Right To Recover Product In Current Year
ProvisionForRightToRecoverProductInCurrentYear
2147000 usd
agio Contract With Customer Current Year Reserve Provisions
ContractWithCustomerCurrentYearReserveProvisions
4697000 usd
agio Prior Year Provision For Contractual Adjustments
PriorYearProvisionForContractualAdjustments
0 usd
agio Prior Year Provisions For Rebate Reserve
PriorYearProvisionsForRebateReserve
-7000 usd
agio Provision For Right To Recover Product In Prior Years
ProvisionForRightToRecoverProductInPriorYears
0 usd
agio Contract With Customer Prior Years Reserve Provisions
ContractWithCustomerPriorYearsReserveProvisions
-7000 usd
agio Contract With Customer Contract Adjustment Recoveries Current Year
ContractWithCustomerContractAdjustmentRecoveriesCurrentYear
793000 usd
agio Contract With Customer Rebate Reserve Recoveries In Current Year
ContractWithCustomerRebateReserveRecoveriesInCurrentYear
495000 usd
agio Contract With Customer Right To Recover Product Current Year Recoveries
ContractWithCustomerRightToRecoverProductCurrentYearRecoveries
1958000 usd
agio Contract With Customer Current Year Reserve Recoveries
ContractWithCustomerCurrentYearReserveRecoveries
3246000 usd
agio Contract With Customer Contract Adjustment Recoveries Prior Year
ContractWithCustomerContractAdjustmentRecoveriesPriorYear
49000 usd
agio Contract With Customer Rebate Reserve Recoveries In Prior Years
ContractWithCustomerRebateReserveRecoveriesInPriorYears
306000 usd
agio Contract With Customer Right To Recover Product Prior Year Recoveries
ContractWithCustomerRightToRecoverProductPriorYearRecoveries
48000 usd
agio Contract With Customer Prior Years Reserve Recoveries
ContractWithCustomerPriorYearsReserveRecoveries
403000 usd
CY2023Q3 agio Contract With Customer Contractual Adjustment Reserve
ContractWithCustomerContractualAdjustmentReserve
142000 usd
CY2023Q3 agio Contract With Customer Rebate Reserve
ContractWithCustomerRebateReserve
1396000 usd
CY2023Q3 agio Contract With Customer Right To Recover Product Reserve
ContractWithCustomerRightToRecoverProductReserve
274000 usd
CY2023Q3 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
1812000 usd
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
137000 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
60000 usd
CY2023Q3 agio Contract With Customer Allowance And Reserves Liability
ContractWithCustomerAllowanceAndReservesLiability
1675000 usd
CY2022Q4 agio Contract With Customer Allowance And Reserves Liability
ContractWithCustomerAllowanceAndReservesLiability
711000 usd
CY2023Q3 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
1812000 usd
CY2022Q4 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
771000 usd
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
2206000 usd
agio Contract With Customer Asset Revenue Recognized
ContractWithCustomerAssetRevenueRecognized
24411000 usd
agio Contract With Customer Asset Proceeds From Collection Of Receivables
ContractWithCustomerAssetProceedsFromCollectionOfReceivables
25441000 usd
CY2023Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
1176000 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5772564 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
48.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
870924 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
25.88
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
188591 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
11.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
912479 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
55.49
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5542418 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
45.37
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3485110 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
54.14
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5542418 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
45.37
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9076000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11156000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30952000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
37831000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9076000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11156000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30952000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
37831000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6909788 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6909788 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7183967 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7183967 shares
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001439222-23-000140-index-headers.html Edgar Link pending
0001439222-23-000140-index.html Edgar Link pending
0001439222-23-000140.txt Edgar Link pending
0001439222-23-000140-xbrl.zip Edgar Link pending
agio-20230930_lab.xml Edgar Link unprocessable
agio-20230930.htm Edgar Link pending
agio-20230930.xsd Edgar Link pending
exhibit31-1x09x30x23.htm Edgar Link pending
exhibit31-2x09x30x23.htm Edgar Link pending
exhibit32-1x09x30x23.htm Edgar Link pending
exhibit32-2x09x30x23.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
agio-20230930_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
agio-20230930_def.xml Edgar Link unprocessable
agio-20230930_pre.xml Edgar Link unprocessable
agio-20230930_cal.xml Edgar Link unprocessable